In a combination chemotherapy plan, which approach best ensures patient safety?

• A. The toxicity of each drug involved
• B. Monitor only after treatment ends
• C. Only the most toxic drug
• D. No monitoring

Answer: (A)

Assessing toxicity from each drug throughout the course of combination chemotherapy is essential for patient safety. When therapy involves more than one agent, each drug has its own potential adverse effects and they can compound or interact; continuous monitoring lets clinicians detect early signs of toxicity, adjust doses, and provide supportive care to prevent progression to severe harm. This includes baseline and periodic labs (blood counts, liver and kidney function), assessment of symptoms, and timing adjustments to minimize overlapping toxicities. By catching problems early, you reduce the risk of complications like neutropenia, infection, organ injury, or treatment discontinuation, and you keep the patient on the intended treatment plan safely. Waiting until after treatment ends fails to identify acute or cumulative toxicities, and focusing only on the most toxic drug ignores other contributors to patient risk. Not monitoring at all is unsafe because adverse effects can develop at any point and early intervention improves outcomes.